Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- House
- Sponsors
- 7
- Latest action
- Mar 3, 2025
What it does
The bill amends the Public Health Service Act to reauthorize and expand a sickle cell disease prevention and treatment demonstration program by increasing funding from $4.455 million annually (2019–2023) to $8.205 million annually (2025–2029) and broadening the program’s scope to include the prevention and treatment of complications of sickle cell disease, not just the disease itself. It also changes the funding mechanism to allow grants, contracts, or cooperative agreements instead of only contracts. The bill expresses congressional support for further research into the causes and potential cures for heritable blood disorders, including sickle cell disease. It affects public health…
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.